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A novel steroid – pyrrolidinoisoquinoline alkaloid hybrid has been successfully synthesized by Diels-Alder reaction 
N-acyliminium ion cyclization sequence. 
Keywords: Hybrid, steroid, pyrrolidinoisoquinoline alkaloid, N-acyliminium ion, Diels-Alder reaction 
Novel molecules which may exhibit biological activity 
have always attracted the attention of synthetic 
chemists. Nature is playing a pivotal role in providing 
enticing molecules through mixed biosynthetic routes. 
For example, Taipaienine
1
 1 is a combination of 12-





 3 are illustrative examples of steroid-
alkaloid conjugates. Ritterazine
4
 4 is yet another 
example of molecular entity having a dimeric steroidal-
alkaloid structure (Figure 1). 
Newer molecular entities can be generated by 
combining structural features of two or more different 
class of compounds. Molecules generated in this way 
are commonly referred to in the literature as ‘hybrids’
5
 
or ‘conjugates. Among these hybrids, steroidal hybrids
6
 
are unique due to their broad biological activity profile 
and their ability to penetrate the cell membrane. 
Reports
7
 dealing with steroid-alkaloid hybrid have 
particularly captured our attention. The biological 
activity associated with pyrrolidino-isoquinoline 
alkaloid
8
 prompted us to synthesize its steroidal 
analogue. 
 
Results and Discussion 
In this paper, we wish to report a novel steroid-
pyrrolidino-isoquinoline alkaloid hybrid. Our strategy 
is based on Diels-Alder reaction followed by  
N-acylinimium ion cyclization9. The retrosynthetic 
approach of our scheme is depicted below in Figure 2. 
In light of the estrogen-anthracenedione hybrid 
work, reported by De Riccardis et al.
10
, we decided to 
synthesize a novel molecular entity through the fusion 
of pregnenolone11 and hexahydropyrroloisoquinoline12 
moieties. In this context, diene 7 was prepared from  
16 –DPA, 9 (Scheme I) following the method reported 
by Wu and Yang group
13
. Diels-Alder addition of diene 
7 (1 mmol) and maleimide 8 (1mmol), followed by acid 
hydrolysis of the cycloadduct resulted into a mixture of 
presumably two isomeric polycyclic keto-imide 6. Since 
all our efforts to resolve the mixture were unsuccessful, 
it was thought desirable to subject the keto-imide 6 to 
borohydride reduction
9,12,14
 with a hope that the two 
components may separate at latter stage. 
 
Our choice of reducing the keto-imide was governed 
by the fact that N-(2’-phenylethyl)-α-hydroxy lactams 
derivable from such amides are known for elaboration 
to 13-aza-steroid ring
15
 system on acid catalyzed 
cyclization. The keto-imide 6 was, therefore, reduced 
to a diol 10 which was subsequently subjected to acid 
catalyzed cyclization. The resultant molecular entity 
was then crystallized from pet ether-ethyl acetate (3:2) 
which resulted into a colorless crystalline compound16 
5 (Scheme II). 
 
Having synthesized a molecule with the gross 
features of the desired steroid-pyrrololidinoisoquino 
line alkaloid hybrid; the most difficult and challenging 
task before us was to establish the stereochemistry at 
all new stereocenters generated during the process. 
Based on the literature available
17
, it was expected that 
between C24 and C25 carbonyls, the latter one will 
preferentially get reduced upon borohydride reduction 
and this selectivity could be attributed to the steric 
hindrance offered by the C15 methylene protons of ring 
D. Literature
13,18
 lends support for the α-orientation of 
C17 hydrogen, and the stereochemistry of the hydroxyl 




group located at C20 was similarly deduced to be α
19
. 
Taking steric repulsions into account, one may assume 
that the annulation of the acyliminium ion will proceed 
from the less hindered β face. The orientation of the 
hydrogen at the ring juncture (at C25) will therefore be 
α
9,12,14
. Finally, the structure of hybrid 5 was 
unambiguously established by single crystal X-ray 





Synthesis of steroidal diene 7 
To an ice-cooled solution of 9 (0.712 g, 2 mmol) in 
anhydrous ether (30 ml) was added drop wise 
triethylamine (332 µl, 2.4 mmol) and tert-
butyldimethylsilyl triflate (0.5 ml, 2.2 mmol). After 
stirring at 0°C for 15 minutes and then at RT for 30 
minutes, the mixture was concentrated under reduced 
pressure, then passed through a pad of Al2O3 





Synthesis of cycloadduct 6 
Maleimide 8 (0.370 g, 1.42 mmol) and steroidal 
diene 7 (0.669 g, 1.42 mmol) in toluene (40 mL) were 
refluxed for 8 h and allowed to cool to RT. The solvent 
was removed in vacuo to give cycloadduct which was 
used in the next step without purification. 
Cycloadduct (1 g, 1.36 mmol) was dissolved in 
dichloromethane and treated with conc. HCl (0.5 ml). 
The resulting solution was then stirred at RT for 2 h. 
The solution was washed with saturated bicarbonate 
solution twice and then with water and brine solution, 
dried over Na2SO4 and concentrated in vacuo to give 
6 which was purified by column chromatography 



















Acid catalysed cyclization of hydroxyl imide 
The cyclo adduct 6 (0.36 g, 0.582 mmol) in MeOH: 
DCM (9 ml + 3 ml) at −10°C, with out further 
characterization, was treated with sodium borohydride 
(0.1 g, 2.64 mmol). After addition was complete, the 
mixture was stirred at 0°C for 4 h and then at RT for 1 h. 
Solvent was removed in vacuo and residue was diluted 
with water and extracted thrice with dichloromethane. 
The combined organic layer was washed with brine, 
dried over Na2SO4 and concentrated in vacuo. Column 
chromatographic purification in ethyl acetate: hexane 
(1/4) gave imide alcohol as a colourless solid. The 
resulting hydroxy imide was carried forward to acid 
catalysed cyclization. Hydroxy imide (0.3 g, 0.484 
mmol) was dissolved in dichloromethane and treated 
with (0.5 ml) conc. HCl. The resulting solution was then 
refluxed for 10 h. Reaction mixture was then poured 
over saturated aqueous NaHCO3 (10 mL). The mixture 
was extracted thrice with CH2Cl2. The combined organic 
layer was dried over Na2SO4 and concentrated. Column 
chromatography (EtOAc-hexane 3/7) gave unidentified 
mixture as colorless solid; whose fractional 
crystallization resulted into a crystalline compound 
which was unambiguously characterized as the required 
steroidal hybrid 5. 
 
Spectral data for compound 5 
Colourless solid; m.p.> 200°C. IR (KBr): 3459, 





(300 MHz, CDCl3): δ 6.6 (1H, s), 6.5 (1H, s), 5.3 (1H, 
s), 4.2 (2H, m), 3.8 (3H, s), 3.8 (1H, s), 3.8 (3H, s), 3.5 
(1H, m), 3.0 (2H, m), 2.5 (4H, m), 2.2 (4H, m), 1.9-1.0 
(15 H, m), 1.0 (3H, s), 0.8 (3H, s); 
13
C NMR (75 MHz, 
CDCl3): δ 175.9, 148.0, 147.5, 140.4, 127.5, 126.9, 
121.7, 111.9, 107.5, 71.5, 70.8, 61.9, 59.4, 56.0, 55.8, 
55.0, 50.2, 43.2, 42.2, 41.9, 39.9, 39.6, 38.9, 38.7, 38.0, 
37.2, 36.5, 31.6, 31.5, 31.4, 27.1, 25.4, 20.5, 19.3, 12.3; 






Thus, a novel steroid-pyrrolidinoisoquinoline 
alkaloid hybrid with six new stereo-defined centers 
has been successfully synthesized via Diels-Alder 
reaction- N-acyliminium ion cyclization sequence. 
Absolute configuration of the hybrid molecule 5 has 
been established from its X-ray structure. 
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